Table 1.
Total n = 60 | Survivors n = 46 | Non-survivors n = 14 | pa | |
Gender (male) | 35 (58%) | 27 (59%) | 8 (57%) | 0.918 |
Age (years) | 43 ± 16 | 42 ± 16 | 47 ± 17 | 0.479 |
SBP, measurable at hospital arrival | 42 (70%) | 36 (78%) | 6 (43%) | 0.011 |
Injury mechanism | ||||
Fall from height | 29 (48%) | 24 (52%) | 5 (36%) | 0.281 |
MVC | 15 (25%) | 11 (24%) | 4 (29%) | 0.724 |
Pedestrian | 11 (18%) | 7 (15%) | 4 (29%) | 0.258 |
Cyclist | 3 (5%) | 2 (4%) | 1 (7%) | 0.674 |
Other | 2 (3%) | 2 (4%) | 0 (0%) | 1.000 |
ISS (0–75) | 41 ± 18 | 37 ± 16 | 53 ± 19 | 0.006 |
RTS (0–8) | 5.1 ± 2.0 | 5.6 ± 1.9 | 3.4 ± 1.7 | 0.001 |
TRISS (0–100%) | 45.9 (0.4–98.9) | 65.9 (2.2–98.9) | 5.9 (0.4–57.6) | <0.001 |
Time to CT (minutes) | 50 (14–327) | 50 (14–327) | 50 (30–101) | 0.965 |
Pelvic fracture pattern | ||||
Type A | 8 (13%) | 7 (15%) | 1 (7%) | 0.667 |
Type B | 20 (33%) | 17 (37%) | 3 (21%) | 0.347 |
Type C | 32 (53%) | 22 (48%) | 10 (71%) | 0.140 |
Acetabular fracture | 13 (22%) | 11 (24%) | 2 (14%) | 0.444 |
Associated injuries | ||||
Head | 29 (48%) | 19 (41%) | 10 (71%) | 0.056 |
Spine | 50 (83%) | 38 (83%) | 12 (86%) | 1.000 |
Chest | 50 (83%) | 36 (78%) | 14 (100%) | 0.098 |
Liver | 17 (28%) | 14 (30%) | 3 (21%) | 0.737 |
Spleen | 12 (20%) | 10 (22%) | 2 (14%) | 0.713 |
Kidney | 17 (28%) | 12 (26%) | 5 (36%) | 0.511 |
Other | 39 (65%) | 29 (63%) | 10 (71%) | 0.565 |
Angiography | 16 (27%) | 13 (28%) | 3 (21%) | 0.740 |
30-day mortality | 14 (23%) | |||
Blood transfusion within 24 h (units) | ||||
RBC | 10 (0–96) | 7 (0–96) | 22 (0–40) | 0.011 |
Plasma | 10 (0–110) | 8 (0–110) | 19 (0–44) | 0.076 |
Platelets | 0 (0–20) | 0 (0–20) | 2 (0–6) | 0.036 |
ISS, injury severity score; MVC, motor vehicle collision; RBC, red blood cells; RTS, revised trauma score; SBP, systolic blood pressure; TRISS, trauma score-injury severity score (probability of survival).
Data are presented as n (%), means ± SD or median (min–max).
Statistical significant results are marked with bold text.
Comparison between survivors and non-survivors.